Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2021-05-04, Stock:NVS, The news for the past five days is as follows:
2021-04-27: NEWS1: Novartis Generics Face 'Challenging Quarter,' But Gene Therapy Shines.NEWS2: Eli Lil­ly Aban­dons IL-23 Psoriasis Program, Instead Will Focus On Ulcerative Colitis, Crohn's Disease Indications.NEWS3: ANI Pharmaceuticals, Inc. -- Moody's assigns first-time B2 CFR to ANI Pharmaceuticals; outlook stable.NEWS4: Novartis (NVS) Q1 2021 Earnings Call Transcript.NEWS5: Novartis (NVS) Q1 Earnings & Sales Miss Estimates on COVID-19 Woes.NEWS6: Why Novartis Missed Wall Street Q1 Estimates.NEWS7: Novartis Earnings, Sales Slightly Miss Q1 Views.NEWS8: Novartis Earnings, Sales Slightly Miss First-Quarter Views.NEWS9: Italy judge sends Bayer, Novartis to trial in drugs fraud probe: sources.NEWS10: Italy judge sends Bayer, Novartis to trial in drugs fraud probe - sources.NEWS11: Novartis Q1 Earnings Take A Hit Amid COVID-19 Impact.NEWS12: Novartis key growth drivers and launches continue momentum in Q1, maintaining confidence in growth. Group guidance for FY 2021 confirmed..NEWS13: Novartis warns of pandemic delay in cancer diagnoses.
2021-04-28: nan
2021-04-29: NEWS1: Eaton Vance Worldwide Health Sciences Fund's Top 4 1st-Quarter Trades.
2021-04-30: NEWS1: The Eaton Vance Fund sells Novartis, Pfizer.NEWS2: Pharma Stock Roundup: Big Drugmakers' Q1 Earnings, Resumption of JNJ US COVID-19 Jabs.NEWS3: Alnylam's (ALNY) Q1 Loss Narrower Than Expected, Revenues Beat.
2021-05-03: NEWS1: 3 High-Yield Stocks for Dividend Investors.NEWS2: Novartis' Beovu Non-Inferior To Aflibercept In Phase 3 Diabetic Macular Edema Study.NEWS3: The Zacks Analyst Blog Highlights: Eli Lilly, Merck, GlaxoSmithKline, Novartis and Johnson & Johnson.NEWS4: Novartis biosimilar targets rivals' Eylea eye treatment.NEWS5: Sandoz confirms late-stage clinical development plans for proposed biosimilar aflibercept, a key ophthalmology medicine.

Answer: Decrease